Antitumor Assessment
Overview
The Antitumor Assessment (ATA) Core provides support for early discovery and in vivo testing of antitumor detection and therapeutic agents. The Core provides resources, professional and technical expertise, and advisory services related to the evaluation of agents with potential diagnostic or therapeutic activity. The ATA Core works closely with investigators to establish preclinical models, including Patient-Derived Xenograft (PDX) and Patient-Derived Organoid (PDO) models, for the design and execution of pharmacokinetic (PK), toxicity, and in vivo efficacy studies. The Core also assists investigators in determining the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. As such, the Core provides a major vehicle to facilitate preclinical studies, including Good Laboratory Practice (GLP)-compliant safety toxicology studies in support of Investigational New Drug (IND) applications, and is a major contributor to the translational mission of the Center. The Core helps investigators design, plan, and execute in vivo experiments, prepare animal protocols and grant applications involving animal studies, and analyze and summarize data for publication and for IND reporting. Importantly, the ATA Core acts as a central coordinator for studies involving support from several Shared Resources and centralized services at MSK (including Animal Imaging, Center for Comparative Medicine & Pathology, Integrated Genomics Operation, Organic Synthesis, Radiochemistry and Molecular Imaging Probes, and Molecular Cytology Cores, as well as MSK’s Tissue Procurement Service) so that studies are conducted properly and in a time- and cost-efficient manner.
Featured News
People
Members
